Portfolio Companies

Gothenburg, October 1, 2019 – Following the successful dose escalation phase I study, Vicore Pharma Holding AB (publ), a pharmaceutical company dedicated to developing innova...
Read more

Paris, France, October 1, 2019, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering a...
Read more

Oslo, Norway, 1 October 2019 Nordic Nanovector ASA (OSE: NANO) announces the appointment of Dr Gabriele Elbl as Vice President Global Regulatory Affairs. Dr Elbl is a ph...
Read more

Stockholm – September 26, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that the last patient has been included in the OP-106 HORIZON pivotal phase 2 clin...
Read more

DUBLIN, Ireland and TREVOSE, Pa., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company fo...
Read more

Oslo, Norway, 24 September 2019 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today ann...
Read more

Clinically meaningful improvement of 25 ETDRS letters equivalent versus nadir of BCVA in GS010-treated eyes at 96 weeks Results coherent with those of REVERSE: durable bilat...
Read more

~ RECORLEV Resulted in Sustained Improvements in Urinary Free Cortisol (UFC) and Provided Clinical Benefit, As Demonstrated By Improvements in Comorbidities...
Read more

Lund, Sweden, 19.00 CET, 18 September 2019 – BONESUPPORT HOLDING AB, listed on Nasdaq Stockholm - an emerging leader in orthobiologics for the management of bone voids announced...
Read more

17.09.2019 07:00 Clinical          LYMRIT 37-01 (relapsed iNHL) - median duration of response of 13.6 months for all responders and 32.0 months for complet...
Read more